Abstract 3020
Background
Oncogenic BRAF-V600 mutations are observed in 1-2% of NSCLC. Targeted therapies (TT) including vemurafenib (V), dabrafenib (D) or dabrafenib plus trametinib (D+T) are associated with favorable outcomes in these patients (pts). The mechanisms of resistance to BRAF-TT in NSCLC are largely unknown.
Methods
We performed genomic profiling of serial ctDNA in 79 metastatic BRAF-mutant NSCLC pts (96% V600E, 4% non-V600). BRAFstatus was ascertained based on local testing. Plasma samples were collected, from 2014-2018 in 27 hospitals, from pts treated with V (n = 34), D (n = 2) or D+T (n = 23). We collected 41 plasma samples at baseline to BRAF-TT, 40 at progressive disease (PD) and ∼200 during treatment follow-up, concurrent to routine radiological evaluation. Inivata InVisionSeq™ assay was used to detect the presence of genomic alterations in 36-cancer related genes.
Results
At baseline, 72.5% of BRAF mutations were detected in plasma. BRAF-V600E detection in plasma was associated with the presence of liver metastasis (22%), versus BRAF-V600E negative pts (7%). Co-occurring alterations at baseline were observed in 18/26 (70%) pts: FGFR2 (1pt), PIK3CA (2pts), ERBB2 (1pt), CTNNB1 (2pts) and IDH1 (2pts). FGFR2, PIK3CAor CTNNB1 alterations were associated with PD as the best response to subsequent BRAF-TT. Complete clearance of baseline BRAF-V600E in ctDNA was observed at the 1stCT-scan evaluation in 42% (3/7) and 82% (9/11) pts who responded to V or D+T, respectively. At PD, a consistent rebound in BRAF-V600E plasma levels was observed in 60% (24/40) pts. PD to V was associated with alterations in the MAPK pathway: KRAS(1pt), GNA11 (1pt), NRASand GNAS (1pt) and MAP2K1and NFE2L2 (1pt). Activating PI3KCA mutations were observed in 4 pts who progressed in < 6 months on V. Similar to pts who progressed on V, alterations in KRAS, NRAS, PIK3CAand CTNNB1were associated with D+T resistance. The impact of these alterations was assessed by in silico structure modeling.
Conclusions
ctDNA monitoring might be an informative tool for assessing disease response and and understand mechanisms of resistance in BRAF-mutant NSCLC pts treated with BRAF-TT. MAPK reactivation remains an important resistance mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sandra Ortiz-Cuaran, David Planchard, Jean-Yves Blay, Pierre Saintigny.
Funding
Fondation ARC (PJA 2017-1206573).
Disclosure
L. Mezquita: Advisory / Consultancy: Roche Diagnostics; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Lectures and educational activities: Tecnofarma; Advisory / Consultancy, Lectures and educational activities: Roche; Advisory / Consultancy, Lectures and educational activities: AstraZeneca; Travel / Accommodation / Expenses: Chugai. J. Mazieres: Advisory / Consultancy: Roche; Research grant / Funding (self): Roche; Advisory / Consultancy: Novartis. K. Howarth: Shareholder / Stockholder / Stock options: Inivata Ltd; Full / Part-time employment: Inivata Ltd. C. Morris: Shareholder / Stockholder / Stock options: Inivata Ltd; Full / Part-time employment: Inivata Ltd. E. Green: Shareholder / Stockholder / Stock options: Inivata Ltd; Full / Part-time employment: Inivata Ltd. M. Perol: Advisory / Consultancy: Roche ; Advisory / Consultancy: Novartis. B. Besse: Research grant / Funding (institution): AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma. J. Blay: Research grant / Funding (institution), Travel grants: Roche; Research grant / Funding (institution), Travel grants: Novartis. P. Saintigny: Advisory / Consultancy: HTG Molecular; Research grant / Funding (institution): BMS, AstraZeneca, Roche, HTG Molecular. D. Planchard: Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, MedImmune, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Research grant / Funding (institution): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho ; Travel / Accommodation / Expenses: AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract